Core Insights - Rapid Micro Biosystems, Inc. reported a significant 20% year-over-year revenue growth for the full year 2025, driven by key commercial wins and an expanding customer base for its Growth Direct platform [2][8][9]. Financial Performance - Total revenue for Q4 2025 was $11.3 million, a 37% increase from $8.2 million in Q4 2024 [3][8]. - For the full year 2025, total revenue reached $33.6 million, up from $28.1 million in 2024, marking a 20% growth [9]. - Product revenue in Q4 2025 increased by 78% to $9.3 million compared to $5.2 million in Q4 2024 [3]. - Service revenue decreased by 34% to $2.0 million in Q4 2025, attributed to the volume of validation activities [3]. - Recurring revenue rose by 10% to $4.6 million in Q4 2025, compared to $4.2 million in Q4 2024 [3]. Cost and Margin Analysis - Total cost of revenue for Q4 2025 was $11.6 million, up from $7.2 million in Q4 2024, resulting in a gross margin percentage of negative 3% compared to positive 12% in Q4 2024 [4][10]. - For the full year 2025, total cost of revenue was $32.5 million, leading to a gross margin percentage of 3%, an improvement from 0% in 2024 [10]. Operating Expenses - Total operating expenses in Q4 2025 increased by 6% to $11.9 million compared to $11.2 million in Q4 2024 [5]. - Research and development expenses decreased by 5%, while sales and marketing and general and administrative expenses both increased by 11% compared to Q4 2024 [5]. Net Loss - The net loss for Q4 2025 was $12.5 million, compared to $9.7 million in Q4 2024, with a net loss per share of $0.28 [6][11]. - For the full year 2025, the net loss was $47.1 million, slightly higher than the $46.9 million loss in 2024, with a net loss per share of $1.05 [11]. Future Outlook - The company anticipates total revenue for 2026 to be between $37.0 million and $41.0 million, with expected placements of 30 to 38 Growth Direct systems and a gross margin percentage of approximately 20% [8][12].

Core Insights - Rapid Micro Biosystems, Inc. is participating in the KeyBanc Capital Markets Healthcare Forum, highlighting its role in the life sciences technology sector [1] - The company will hold a virtual Q&A session on March 17, 2026, at 11:15 a.m. Eastern Time, with a live webcast available for investors [2] Company Overview - Rapid Micro Biosystems provides automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The flagship Growth Direct system modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, operational efficiency, and compliance with data integrity regulations [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3]

Core Viewpoint - Rapid Micro Biosystems, Inc. is set to present at the TD Cowen 46th Annual Health Care Conference, highlighting its innovative automation solutions for healthcare product manufacturing and quality control [1][2]. Company Overview - Rapid Micro Biosystems is a life sciences technology company focused on automation solutions that enhance the manufacturing and release processes of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3]. - The company's flagship product, the Growth Direct system, modernizes microbial quality control (MQC) testing workflows, improving efficiency and compliance in pharmaceutical manufacturing [3]. - The company is headquartered in Lexington, Massachusetts, with manufacturing operations in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3].

Core Insights - Rapid Micro Biosystems, Inc. will release its fourth quarter and full year 2025 financial results on March 12, 2026, before the market opens [1] - A webcast conference call will be hosted by the management team at 8:30 a.m. ET on the same day, with a live audio webcast available on the company's website [2] Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The company's flagship product, the Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, operational efficiency, and compliance with data integrity regulations [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3]

Financial Performance & Growth - Total revenue for 2025 reached $33.6 million, representing a 20% year-over-year growth[13] - Recurring revenue accounted for $17.8 million in 2025, making up 53% of the total revenue[14] - The company achieved a significant gross margin improvement in 2025[14] - Q4 2025 total revenue was $11.3 million, a 37% growth[14] Market Position & Strategy - Rapid Micro Biosystems' Growth Direct system is used by 75% of the top 20 global pharmaceutical companies[13, 34] - 86% of approved CAR-T manufacturers have placed Growth Direct systems[13, 35] - The company has a land and expand strategy, focusing on enterprise deployments and new geographies[31, 32] - The company has 190 cumulative system placements[13, 35] Technology & Innovation - The Growth Direct platform automates microbial quality control (MQC), reducing the process to 2 steps and halving the time to results[25] - The company has 155 cumulative system validations[13, 35] Partnerships - Strategic partnership with MilliporeSigma is expected to drive growth, margin expansion, and innovation[14]

Core Insights - The company reported preliminary unaudited revenue for Q4 and full year 2025, indicating strong growth in both periods [1][4]. Q4 2025 Performance - Q4 2025 revenue is expected to be approximately $11.3 million, reflecting a growth of about 37% compared to the same period last year [2][8]. - Recurring revenue for Q4 2025 is anticipated to be around $4.6 million, showing a growth of approximately 10% year-over-year [2]. - The company achieved a record placement of 16 new Growth Direct systems and completed the validation of three customer systems in Q4 [2]. Full Year 2025 Performance - Total revenue for the full year 2025 is projected to be approximately $33.6 million, representing a growth of about 20% compared to the previous year [3][8]. - Recurring revenue for the full year is expected to be around $17.8 million, indicating a growth of approximately 15% year-over-year [3]. - The company placed a total of 28 new Growth Direct systems and validated 18 customer systems throughout 2025, bringing the cumulative total to 190 systems placed globally with 155 validated [3]. Management Commentary - The President and CEO expressed satisfaction with the record results for Q4, which exceeded the raised guidance from November [4]. - The company is positioned for continued growth in 2026, supported by a strong execution track record and advancements in its strategic partnership with MilliporeSigma [4]. Upcoming Events - The company is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, with a live webcast available for investors [6].

Core Viewpoint - Rapid Micro Biosystems, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its innovative automation solutions for healthcare product manufacturing and quality control [1][2]. Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions aimed at improving the manufacturing and release processes of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3]. - The company's flagship product, the Growth Direct system, modernizes microbial quality control (MQC) testing workflows, enhancing operational efficiency, accuracy, and compliance with data integrity regulations [3]. - The company is headquartered in Lexington, Massachusetts, with manufacturing facilities in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3].

Core Insights - Rapid Micro Biosystems reported strong third quarter results with total revenue of $7.8 million, a 3% increase from $7.6 million in the same quarter of 2024 [3][8] - The company achieved record consumable revenue and a 32% increase in recurring revenue compared to the previous year, driven by strong service growth [2][8] - A significant multi-system order was received from a top global biopharma customer, marking the largest order in the company's history, which is expected to contribute to growth in 2026 and beyond [2][9][10] Financial Performance - Total revenue for Q3 2025 was $7.8 million, up 3% from $7.6 million in Q3 2024, with product revenue remaining flat at $5.2 million and service revenue increasing by 12% to $2.6 million [3][8] - Recurring revenue rose by 32% to $4.8 million compared to $3.7 million in Q3 2024, indicating strong demand for consumables and service contracts [3][8] - Gross margin improved to 9%, up from 8% in the previous year, reflecting better cost management [4][8] Cost Management - Total cost of revenue increased by 2% to $7.1 million in Q3 2025, while total operating expenses decreased by 5% to $12.1 million [4][5] - General and administrative expenses decreased by 1%, R&D expenses decreased by 2%, and sales and marketing expenses saw a significant drop of 14% compared to Q3 2024 [5] Net Loss and Cash Position - The net loss for Q3 2025 was $11.5 million, slightly higher than the $11.3 million loss in Q3 2024, with net loss per share remaining at $0.26 for both periods [6][8] - As of September 30, 2025, the company had approximately $42 million in cash, cash equivalents, short-term investments, and restricted cash [6][22] Future Outlook - The company raised its full-year 2025 total revenue guidance to at least $33 million, anticipating at least 27 Growth Direct system placements [10]

Core Insights - Rapid Micro Biosystems, Inc. is participating in the Stifel 2025 Healthcare Conference in New York, NY on November 11, 2025 [1][2] Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The company's flagship product, the Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, operational efficiency, and compliance with data integrity regulations [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3]

Core Insights - Rapid Micro Biosystems, Inc. will release its third quarter 2025 financial results on November 7, 2025, before market opening [1] - The management team will host a webcast conference call at 8:30 a.m. ET on the same day, which will be accessible on the company's website [2] Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions for the efficient manufacturing and safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3] - The company's flagship product, the Growth Direct system, modernizes microbial quality control testing workflows in pharmaceutical manufacturing, enhancing speed, accuracy, operational efficiency, and compliance with data integrity regulations [3] - The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell, Massachusetts, and additional locations in Switzerland, Germany, and the Netherlands [3]